Mpi: First Patient Dosed In Phase 2 Study Of The Parp Inhibitor 2x121 For Breast Cancer | Latest News RSS feed

Mpi: First Patient Dosed In Phase 2 Study Of The Parp Inhibitor 2x121 For Breast Cancer - Latest News


MPI: First Patient dosed in Phase 2 Study of the PARP Inhibitor 2X-121 for Breast Cancer

Hoersholm, Denmark, June 26, 2018 - Medical Prognosis Institute A/S (MPI ... dosing of the first patient in a Phase 2, clinical study to investigate the anti-tumor effect and tolerability of 2X-121 in ... read more

MPI - Strong LiPlaCis Treatment Results in DRP-Selected Breast Cancer Patients - Collaborative LiPlaCis Regulatory Meeting with DKMA

2018 -Medical Prognosis Institute (Nasdaq First North; MPI:ST) and Oncology Venture Sweden AB (OV.ST) ("OV" or "the Company") announce the third interim report from the ongoing LiPlaCis® Phase 2 study ... read more

Oncology Venture Announces Abstracts on Three Pipeline Products Selected for 2018 ASCO Clinical Meeting

Notably, Ruth Plummer, MD, PhD, FRCP, will present an abstract describing the first-in-human Phase 1 study of 2X-121, an investigational PARP 1/2 and tankyrase 1/2 inhibitor ... tolerability of 2X121 ... read more

Looking for another news?


Myriad Genetics: Exciting Alzheimer's Treatment In the Pipeline

All patients in the U.S. phase III study ... PARP (poly-ADPribose polymerase) inhibitor, to treat patients with breast cancer or ovarian cancer associated with an inherited mutation in one of the canc... read more


MPI – Strong LiPlaCis Treatment Results in DRP-Selected Breast Cancer Patients – Collaborative LiPlaCis Regulatory Meeting with DKMA

Furthermore, DKMA indicated that the planned clinical trial will be considered a pivotal Phase 2 study ... Breast Cancer moving on to Multiple Myeloma and Prostate Cancer as the first steps. MPI’s DRP... read more

Status and Up-date on Oncology Venture & SPV pipelines

Response (confirmed PR = Partial Response) has been published for the first DRP-screened patient with a hard to treat metastatic Breast Cancer. LiPlaCis has received status as a phase 2 study by the . ... read more

Myriad Genetics, Inc. F4Q08 (Qtr End 06/30/08) Earnings Call Transcript

Myriad Genetics, Inc. (NASDAQ:MYGN) F4Q08 (Qtr End 06/30/08) Earnings Call Transcript ... dose study in HIV positive, but treatment naïve patients and expect to initiate that study later this year. Ea... read more

First Patient Dosed in Phase 2 Study of PARP/Tankyrase Inhibitor 2X-121 for Metastatic Breast Cancer

(“OV”) and Medical Prognosis Institute A/S (MPI:ST) today announced dosing of the first patient in a Phase 2, open-label clinical trial to investigate the anti-tumor effect and tolerability of 2X-121 ... read more

MPI: First Patient dosed in Phase 2 Study of the PARP Inhibitor 2X-121 for Breast Cancer

"This Phase 2 study will enable us to rapidly evaluate the efficacy of our PARP inhibitor ... with Breast Cancer moving on to Multiple Myeloma and Prostate Cancer as the first steps. MPI`s DRP® tool h... read more

First Patient Dosed in Phase 2 Study of PARP/Tankyrase Inhibitor 2X-121 for Metastatic Breast Cancer

(“OV”) and Medical Prognosis Institute A/S (MPI:ST) today announced dosing of the first patient in a Phase 2, open-label clinical trial to investigate the anti-tumor effect and tolerability of 2X-121 ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us